# Xiaojiao Li
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/xiaojiao-li/
## Facts
| Field | Value |
| --- | --- |
| Citations | 481 |
| Field | Biosimilars and Bioanalytical Methods |
| h-index | 13 |
| i10-index | 16 |
| Last Known Institution | First Affiliated Hospital of Xi'an Jiaotong University |
| OpenAlex ID | https://openalex.org/A5101923362 |
| ORCID iD | 0000-0002-2936-7864 |
| Works | 44 |
## Researcher papers
- [K+ Efflux Antiporters 4, 5, and 6 Mediate pH and K+ Homeostasis in Endomembrane Compartments](https://scholariq.org/papers/k-sup-sup-efflux-antiporters-4-5-and-6-mediate-ph-and-k-sup-sup-homeostasis-in/)
- [PH13 improves soybean shade traits and enhances yield for high-density planting at high latitudes](https://scholariq.org/papers/ph13-improves-soybean-shade-traits-and-enhances-yield-for-high-density-planting/)
- [Global incidence and death estimates of chronic kidney disease due to hypertension from 1990 to 2019, an ecological analysis of the global burden of diseases 2019 study](https://scholariq.org/papers/global-incidence-and-death-estimates-of-chronic-kidney-disease-due-to/)
- [Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial](https://scholariq.org/papers/safety-pharmacokinetics-and-efficacy-of-donafenib-in-treating-advanced/)
- [A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects](https://scholariq.org/papers/a-phase-i-randomized-single-dose-study-to-evaluate-the-biosimilarity-of-ql1206/)
- [Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects](https://scholariq.org/papers/tolerance-variability-and-pharmacokinetics-of-bevacizumab-biosimilars-in-chinese/)
- [A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men](https://scholariq.org/papers/a-phase-i-clinical-study-comparing-the-tolerance-immunogenicity-and/)
- [Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment](https://scholariq.org/papers/safety-pharmacokinetics-and-pharmacodynamics-of-a-novel-aminobutyric-acid-gaba/)
- [Advances and perspectives in biological control of postharvest fungal decay in citrus fruit utilizing yeast antagonists](https://scholariq.org/papers/advances-and-perspectives-in-biological-control-of-postharvest-fungal-decay-in/)
- [Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects](https://scholariq.org/papers/safety-and-pharmacokinetics-of-a-biosimilar-of-denosumab-kn012-phase-1-and/)
## Researcher topics
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Plant Molecular Biology Research](https://scholariq.org/topics/plant-molecular-biology-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
## Researcher university
- [First Affiliated Hospital of Xi'an Jiaotong University](https://scholariq.org/institutions/first-affiliated-hospital-of-xi-an-jiaotong-university/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.